Aimmune down on safety concerns for peanut allergy therapy

Aimmune Therapeutics Inc. (NASDAQ:AIMT) was off $3.33 (11%) to $26.29 on Monday after the New England Journal of Medicine published full data from the Phase III PALISADE trial of the company's peanut allergy therapy AR101, including detailed safety showing a higher rate of rescue epinephrine use in the active arm vs. placebo arm. The move translates

Read the full 567 word article

User Sign In